Frontage Labs, a US-China CRO, Acquires Concord Biosciences

Frontage Laboratories, a Pennsylvania-Shanghai pre-clinical CRO, acquired Concord Biosciences of Cleveland, Ohio for an undisclosed price. Concord , also a pre-clinical CRO, offers expertise in pharmaceuticals, agricultural, chemical and animal health. Frontage said the acquisition will allow it to offer a complete set of services to pharma clients, while adding agricultural products to its offerings. In 2014, Hangzhou Tigermed Consulting, a clinical-stage CRO, paid $50 million for a 70% equity interest in Frontage. More details.... Stock Symbol: (SHZ: 300347) Share this with colleagues: // //